This Peoria PRP site explains its limits

This site can prepare you for a visit, not diagnose you

On these pages, PRP means platelet-rich plasma, made by separating your blood and keeping plasma with platelets, small blood cells that clump when you bleed, for possible use near soreness. We explain that choice without promising relief.

This site can't examine your joint, tell you why it hurts, or choose care for you. Your clinician must do that.

For knees, the largest careful trial found PRP no better than saline after twelve months, while some other reviews found an edge at certain times. Both results matter.

For the hip joint, pooled studies found that PRP didn't ease pain more than saline. That answer isn't hopeful.

Studies can disagree because clinics separate blood in different ways and keep different amounts of platelets or white blood cells. They also study different sore areas.

You can follow the health-source links shown with the claims if you want the fuller medical reports. We won't turn one report into a promise.

The named clinic, QC Kinetix, offers consultations and regenerative treatments, meaning a clinician examines the sore area before the clinic prepares a blood-based option. That's the clinic named here.

The Phoenix-area clinic owners run this site and benefit when someone books. You'll find the full ownership statement at the bottom of every page.

A talk with your regular doctor may help when you have other health concerns or take several medicines. You don't need to rely on this site alone.

Nothing here replaces prompt care for fever, a hot swollen joint, sudden weakness, or a major loss of movement. Your safety comes first.

Sources

1. In the RESTORE trial - the largest placebo-controlled PRP trial in knee osteoarthritis - 288 adults aged 50+ with symptomatic Kellgren-Lawrence grade 2-3 medial knee OA received three weekly intra-articular injections of leukocyte-poor PRP from a commercial system or saline placebo. At 12 months the mean change in knee pain was -2.1 points with PRP versus -1.8 with saline (difference -0.4; 95% CI -0.9 to 0.2; P=.17) against a minimum clinically important difference of 1.8, and the change in medial tibial cartilage volume was -1.4% versus -1.2% (difference -0.2%; 95% CI -1.9% to 1.5%; P=.81). Twenty-nine of 31 prespecified secondary outcomes showed no significant between-group difference. The authors concluded the findings do not support use of PRP for knee OA.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

2. A systematic review of 105 clinical PRP studies in orthopaedics published 2006-2016 found that only 11 (10%) described the preparation protocol clearly enough for another investigator to repeat it, and only 17 (16%) reported any quantitative metric of the final PRP composition. The authors concluded that the current reporting of PRP preparation and composition does not allow the PRP products actually delivered to patients to be compared between studies.

   Chahla J, Cinque ME, Piuzzi NS, et al. — A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. Journal of Bone and Joint Surgery (American), 2017. DOI: 10.2106/JBJS.16.01374.

3. A meta-analysis of 73 articles covering 5,895 patients quantified the PLACEBO response to intra-articular injection in knee osteoarthritis: statistically and clinically significant improvements in pain, function and quality of life at 1, 3 and 6 months, with responder rates above 50% at each of those points, declining by 12 months. The placebo response was stronger in trials with more female participants and in more recently published trials. This is why an uncontrolled 'our patients improved' figure carries almost no information.

   Previtali D, Boffa A, Di Laura Frattura G, et al. — Placebo response to intra-articular injections in knee osteoarthritis: magnitude, evolution over time, and influencing factors. A systematic review and meta-analysis with meta-regression. EFORT Open Reviews, 2025. DOI: 10.1530/EOR-2025-0022.

4. A network meta-analysis of 11 randomized trials (1353 patients) with HIP osteoarthritis found that for both pain and function, at 2-4 months and at 6 months, NO intervention - corticosteroid, hyaluronic acid or PRP - significantly outperformed an intra-articular saline placebo injection.

   Gazendam A, Ekhtiari S, Bozzo A, et al. — Intra-articular saline injection is as effective as corticosteroids, platelet-rich plasma and hyaluronic acid for hip osteoarthritis pain: a systematic review and network meta-analysis of randomised controlled trials. British Journal of Sports Medicine, 2021. DOI: 10.1136/bjsports-2020-102179.

5. An updated meta-analysis of six randomized trials (422 patients) found no benefit of PRP over placebo for Achilles tendinopathy on VISA-A at 3 months (mean difference 1.7; 95% CI -1.8 to 5.2), 6 months (0.5; 95% CI -8.5 to 9.3) or 1 year (-7.9; 95% CI -27.3 to 11.6), nor on VAS pain at 3 months. Funnel-plot asymmetry suggested publication bias inflating apparent benefits. The authors wrote that PRP should not be used to treat Achilles tendinopathy until high-quality trials show a clear clinical benefit.

   Barreto ESR, Antunes Junior CR, Silva IC, et al. — Is Platelet-rich Plasma Effective in Treating Achilles Tendinopathy? A Meta-analysis of Randomized Clinical Trials. Clinical Orthopaedics and Related Research, 2025. DOI: 10.1097/CORR.0000000000003349.